Clinical Trial Update: Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) [Phase 3]

View source ↗

Summary

Phase 3 trial results for switching virologically suppressed HIV-1 adults to a dolutegravir + rilpivirine regimen from their current ART; results posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)
• Juluca (dolutegravir + rilpivirine)
• Tivicay (dolutegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2017-10-24